Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases
Genome Integrity · 2024 · 15
DOI: 10.14293/genint.14.1.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genome Integrity, 2024. Verfasst von Gavin Yong Quan Ng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Physiological processes that govern the normal functioning of mammalian cells are regulated by a myriad of signalling pathways. Mammalian mitogen-activated protein (MAP) kinases constitute one of the major signalling arms and have been broadly classified into four groups that include extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), p38, and ERK5. Each signalling cascade is governed by a wide array of external and cellular stimuli, which play a critical part in mammalian cells in the regulation of various key responses, such as mitogenic growth, differentiation, stress responses, as well as inflammation. This evolutionarily conserved MAP kinase signalling arm is also important for metabolic maintenance, which is tightly coordinated via complicated mechanisms that include the intricate interaction of scaffold proteins, recognition through cognate motifs, action of phosphatases, distinct subcellular localisation, and even post-translational modifications. Aberration in the signalling pathway itself or their regulation has been implicated in the disruption of metabolic homeostasis, which provides a pathophysiological foundation in the development of metabolic syndrome. Metabolic syndrome is an umbrella term that usually includes a group of closely associated metabolic diseases such as hyperglycaemia, hyperlipidaemia, and hypertension. These risk factors exacerbate the development of obesity, diabetes, atherosclerosis, cardiovascular diseases, and hepatic diseases, which have accounted for an increase in the worldwide morbidity and mortality rate. This review aims to summarise recent findings that have implicated MAP kinase signalling in the development of metabolic diseases, highlighting the potential therapeutic targets of this pathway to be investigated further for the attenuation of these diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
- Department of Physiology, Anatomy & Microbiology, School of Life Sciences, La Trobe University, Bundoora, Victoria, Australia.
ORCID-Profile: Karthik Mallilankaraman, Thiruma V Arumugam, M Prakash Hande
Zitieren
APA
Ng, G. Y. Q., Loh, Z. W., Fann, D. Y., Mallilankaraman, K., Arumugam, T. V., & Hande, M. P. (2024). Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases. Genome Integrity, 15. https://doi.org/10.14293/genint.14.1.004
Vancouver
Ng GYQ, Loh ZW, Fann DY, Mallilankaraman K, Arumugam TV, Hande MP. Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases. Genome Integrity. 2024;15. doi:10.14293/genint.14.1.004
BibTeX
@article{Ng2024,
author = {Ng, Gavin Yong Quan and Loh, Zachary Wai-Loon and Fann, David Y and Mallilankaraman, Karthik and Arumugam, Thiruma V and Hande, M Prakash},
title = {Role of Mitogen-Activated Protein (MAP) Kinase Pathways in Metabolic Diseases},
journal = {Genome Integrity},
year = {2024},
volume = {15},
doi = {10.14293/genint.14.1.004}
}
EUVIMED